louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01892072: VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
Official title: VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatocellular Carcinoma
Keywords: hepatocellular carcinoma
HCC
VEGF signaling pathway
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
Collaborators: name: Guangdong Province, Department of Science and Technology
First posted: 2013-07-03
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: hepatocellular carcinoma patients underwent surgical therapy

Brief summary: The investigators study the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis.

Detailed description: Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in HCC cell lines and tumor tissues. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage HCC. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in HCC cells and its possible mechanism in regulating HCC growth.Therefore,we try to clarify the mechanism of VEGF signal in HCC growth,proliferation and apoptosis.

Eligibility criteria: Inclusion Criteria:

1. hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of hepatocellular carcinoma and alphafetoprotein\>400μg/L；or two or more dynamic imagine with a diagnosis of hepatocellular carcinoma
2. Child-Pugh A or B
3. well preserved renal and hematopoietic Function
4. receive surgical therapy
5. achieve complete section accessed by contrast-enhanced CT

Exclusion Criteria:

1. incomplete section
2. remote metastasis
3. Child-Pugh C
4. combination with other hepatobiliary disease
5. suffer from other tumors concurrently or in last five years

Primary outcomes:
measure: the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.
timeFrame: the day when conducting surgery (day 1)
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: First Affiliated Hospital, Sun Yat-Sen University
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Ming Kuang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00566072: The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial
Official title: The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cytomegalovirus Infections
Keywords: the effect of information on compliance of medication
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2007-12-03
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: 21 patients were randomised to receive instructions and coaching or no intervention on the use and intake of ganciclovir. Intake of medication was measured by an electronic pill box. The duration of the study was 100 days.


Eligibility criteria: Inclusion Criteria:

* men and women between 18 and 65 years old
* de novo kidney transplant patients
* patients who need CMV prophylaxis with ganciclovir during 3 months
* patients who gave informed consent after an oral explanation of the study

Exclusion Criteria:

* patients who are seronegative for CMV virus and who received a kidney from a CMV negative donor
* patients with a creatinin clearance of less than 10 ml/min

Primary outcomes:
measure: relation between compliance of medication towards chemoprophylaxis and occurrence of CMV infection after kidney transplantation
timeFrame: weekly follow-up
Secondary outcomes:
measure: relation between compliance and the instructions which a patient gets about intake of medication
timeFrame: weekly follow-up
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Isabelle Devolder, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00683072: Patient-Ventilator Dyssynchrony: How is the Effect of Management?
Official title: Patient-Ventilator Dyssynchrony: How is the Effect of Management?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Respiratory Failure
Keywords: Ventilator
patient-ventilator asynchrony
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2008-05-23
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Between March 2008 through December 2008, patients admitted to our respiratory intensive care unit for the management of acute respiratory failure were daily screened for the presence of patient-ventilator asynchrony.

Brief summary: Although patient-ventilator asynchrony is a frequent phenomenon, its course following management is unknown. As the aid of a data recording system, we try to observe the consequence of patient-ventilator asynchrony following management. Our target is aimed at the patients with high asynchronization index ( \> 10%) as this group of patients have been shown to have prolonged course in intensive care unit and are also prone to be tracheostomized


Eligibility criteria: Inclusion Criteria:

* patients admitted to respiratory intensive care unit with acute respiratory failure and presence of patient-ventilator asynchrony(AI of more than 10%)
* patient can trigger the ventilator

Exclusion Criteria:

* High oxygen fraction: \> 60%.
* High PEEP need: \> 12cmH2O.
* Hemodynamic unstable: shock
* Central nervous system problem.
* Hyperacitve delirium
* Without informed consent

Primary outcomes:
measure: Asynchrony index (AI). (Number of asynchrony events/total respiratory rate)
timeFrame: 20 minutes after alternation of ventilator settings or any therapeutic means
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: National Cheng-Kung University Hospital
Study officials:
affiliation: National Cheng-Kung University Hospital
name: Chang wen Chen, MD, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT02493972: Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ovarian Cancer With Peritoneal Carcinosis
Keywords: ovarian cancer
peritoneal carcinosis
manual exploration
surgery
GelPort
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
Collaborators: name: Groupement Interrégional de Recherche Clinique et d'Innovation
First posted: 2015-07-10
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a Multicenter prospective diagnostic study.


Eligibility criteria: Inclusion Criteria:

* Over 18 years of age Patient
* Woman presenting a peritoneal carcinosis presumed ovarian origin
* Coelioscopy (1st intent or recurrence) planned or performed in the last 4 weeks for laparotomy. The peritoneal cancer index of Sugarbaker must be available.
* WHO 0 - 2
* Membership in a social security system
* Patient having given her written consent

Exclusion Criteria:

* Male
* Contraindication in the coelioscopy
* Any associated medical or psychological condition which could compromise the capacity of the patient to participate in the study
* Patient deprived of freedom, under guardianship or guardianship

Primary outcomes:
measure: evaluate the number of patients with or without laparotomy after evaluation of the resectability by coelioscopy and coelioscopy more manual exploration
timeFrame: 1 month after inclusion
Secondary outcomes:
measure: Number of patients with complications (eventrations, infections, pains) after manual exploration
timeFrame: 1 month after inclusion
measure: Number of patients with parietal metastases
timeFrame: 1 month after inclusion
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU
city: Caen
country: France
facility: Centre Françis Baclesse
city: Caen
country: France
facility: CHU
city: Nantes
country: France
facility: Institut de Cancérologie de l'Ouest
city: Rouen
country: France
facility: Centre Henri Becquerel
Study officials:
References:
Clinical trial NCT06230172: Early Weaning From Incubator To Crib
Official title: Early Weaning of Infants Less Than 1800 Grams From Incubator To Crib
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hypothermia, Newborn
Body Temperature Changes
Newborn Thermal Injury
Lead sponsor: Augusta University
Sponsor class: OTHER
First posted: 2024-01-30
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The investigators will compare a retrospective control arm with a prospective intervention arm.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine the safety and feasibility of weaning from the incubator at a lower post-natal weight at 1600 grams. Our hypothesis is that early weaning from the incubator to a crib/bassinet is safe and may result in a decrease in length of hospital stay while maintaining appropriate growth velocity. Specific outcomes the investigators will evaluate are the length of hospital stay and growth velocity at early weaning.


Eligibility criteria: Inclusion Criteria:

* Infants with a birth weight \<1600 gm

Exclusion Criteria:

* Infants who have bradycardia (HR\<80 bpm) that require stimulation for resolution.
* Infants who require phototherapy.
* Infants who require respiratory support \>2 liter per minute flow by nasal cannula, oxygen need can vary between 21-100%.
* Infants with major congenital anomalies

Primary outcomes:
measure: Length of hospital stay
timeFrame: From birth date to hospital discharge, assessed up to 52 weeks
Secondary outcomes:
measure: Growth velocity
timeFrame: From birth date to hospital discharge, assessed up to 52 weeks
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Augusta University
state: Georgia
Study officials:
References:
citation: Zecca E, Corsello M, Priolo F, Tiberi E, Barone G, Romagnoli C. Early weaning from incubator and early discharge of preterm infants: randomized clinical trial. Pediatrics. 2010 Sep;126(3):e651-6. doi: 10.1542/peds.2009-3005. Epub 2010 Aug 9.
citation: Shankaran S, Bell EF, Laptook AR, Saha S, Newman NS, Kazzi SNJ, Barks J, Stoll BJ, Bara R, Gabrio J, Childs K, Das A, Higgins RD, Carlo WA, Sanchez PJ, Carlton DP, Pavageau L, Malcolm WF, D'Angio CT, Ohls RK, Poindexter BB, Sokol GM, Van Meurs KP, Colaizy TT, Khmour A, Puopolo KM, Garg M, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health, and Human Development Neonatal Research Network. Weaning of Moderately Preterm Infants from the Incubator to the Crib: A Randomized Clinical Trial. J Pediatr. 2019 Jan;204:96-102.e4. doi: 10.1016/j.jpeds.2018.08.079. Epub 2018 Oct 15.
Clinical trial NCT01461772: Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer
Official title: Comparison of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Concurrent Chemoradiation Therapy With Weekly Carboplatin in Locally Advanced Cervical Cancer: Phase III Multicenter Prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Cervical Cancer
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: Boryung Pharmaceutical Co., Ltd
First posted: 2011-10-28
Enrollment: 21
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Concurrent chemoradiation therapy with weekly cisplatin is the current standard treatment for patients with locally advanced cervical cancer. However, weekly cisplatin is related to renal toxicity and not convenient regimen. Recently, carboplatin has proved to be a good radiosensitizer and less renal toxicity. Weekly carboplatin is more convenient regimen for both patients and physicians. Weekly carboplatin may have similar efficacy with weekly cisplatin and may have more favorable toxicity profile. Therefore, the investigators aimed to evaluate the efficacy and safety of concurrent chemoradiation with weekly carboplatin in patients with locally advanced cervical cancer.


Eligibility criteria: Inclusion Criteria:

* Previously untreated, histologically confirmed cervical cancer
* One of following histologic types Squamous carcinoma, adenocarcinoma, adenosquamous carcinoma
* Age: 20-75 years
* GOG performance status: 0-2
* Adequate organ function Bone marrow: WBC ≥ 3,000/mm3, ANC ≥ 1,500/mm3, Platelet ≥ 100X103/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine \< 1.25 × UNL, Liver : AST, ALT \< 3 × UNL, T- bilirubin \< 1.5 mg/ mm3
* Contraception during study treatment
* Informed consent

Exclusion Criteria:

* Previous chemotherapy or pelvic radiation therapy
* Hormone therapy within 4 weeks
* Concomitant malignancy within 5 years except cured basal cell carcinoma of skin
* Uncontrolled medical disease
* Pregnant or lactating woman
* Etc.

Primary outcomes:
measure: Response rate
timeFrame: 3 months after completion of study treatment
Secondary outcomes:
measure: Number of patients with adverse events as a measure of safety and tolerability
timeFrame: Before each chemotherapy, an average of 1 week
measure: Disease-free survival
timeFrame: 2 years after completion of study treatment
measure: Overall survival
timeFrame: 2 years after completion of study treatment
measure: Quality of life
timeFrame: 3 months after completion of study treatment
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
Clinical trial NCT03064672: Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial
Official title: Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: GBS
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2017-02-27
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This prospective cohort study aims to determine whether maternal and neonatal outcomes are affected by GBS carrier status in women undergoing transcervical balloon catheter insertion.


Eligibility criteria: Inclusion Criteria:

* During the study period and in the absence of contraindications, women anticipating induction of labor with unripe cervix will be screened for eligibility.
* Inclusion criteria are singleton gestation with confirmed cephalic presentation
* Gestational age between 37+0/7 and 41+6/7 weeks'
* Intact membranes
* Reactive non-stress test and Bishop's score \< 6.

Exclusion Criteria:

* Women less than 18 years, with multiple gestation pregnancies, pregnancies with major fetal anomalies, vaginal infection, intrauterine fetal death and those who were not candidates for vaginal delivery (placenta previa, non-cephalic presentation, planned cesarean delivery).

Primary outcomes:
measure: adverse neonatal outcomes
timeFrame: 2-3 days
Secondary outcomes:
measure: composite adverse maternal outcomes
timeFrame: 2-3 days
Other outcomes:
Locations:
Study officials:
affiliation: Hadassah Medical Organization
name: Doron Kabiri, MD
role: STUDY_DIRECTOR
References:
citation: Kabiri D, Hants Y, Yarkoni TR, Shaulof E, Friedman SE, Paltiel O, Nir-Paz R, Aljamal WE, Ezra Y. Antepartum Membrane Stripping in GBS Carriers, Is It Safe? (The STRIP-G Study). PLoS One. 2015 Dec 31;10(12):e0145905. doi: 10.1371/journal.pone.0145905. eCollection 2015.
Clinical trial NCT05736172: 3h of PNE on BDNF and Pain Levels
Official title: Effect of Therapeutic Education on Pain Levels and Brain Neurotrophic Factor in Patients With Chronic Pain.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Pain
Musculoskeletal Pain
Keywords: bdnf
pain neuroscience education
Lead sponsor: Universidad Autonoma de Madrid
Sponsor class: OTHER
Collaborators: name: Universidad Rey Juan Carlos
First posted: 2023-02-21
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The promotion of neuroplasticity in conjunction with strategies for restructuring maladaptive cognitions that largely cause the activation of neural networks that contribute to the perpetuation of pain is therefore a fundamental neurophysiological principle for establishing a neurophysiological basis for pain.

perpetuation of pain, is therefore a fundamental neurophysiological principle for establishing physiotherapy therapeutic to establish therapeutic strategies from physiotherapy that contribute to improve the quality of life of patients with chronic pain. Based on the theory that neurotrophic factors such as BDNF play a fundamental role in the initiation and or maintenance of hyperexcitability of central neurons in pain, we consider that the levels of this neurotrophic factor, such as BDNF, may have an important role in the perpetuation of pain. That the levels of this neurotrophic factor may be modified by the application of a therapeutic education protocol, favoring therapeutic education protocol, favoring a reduction in pain intensity.


Eligibility criteria: Inclusion Criteria:

* males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months
* patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle
* ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent.

Exclusion Criteria:

-Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.

Primary outcomes:
measure: Pain Intensity
timeFrame: three hours
measure: BDNF level
timeFrame: three hours
Secondary outcomes:
measure: Anxiety and Depression (HADS)
timeFrame: 3 hours
measure: Quality of life (EQ-5D)
timeFrame: 3 hours
measure: Pain Catastrophism Scale (PCS)
timeFrame: 3 hours
measure: Pain Severity Level (GCPS-R)
timeFrame: 3 hours
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Silvia Di Bonaventura
Study officials:
affiliation: Universidad Rey Juan Carlos
name: Silvia Di Bonaventura
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04585672: Ammonia Metabolism Assessed by Ammonia Infusion
Official title: Ammonia Metabolism Assessed by Ammonia Infusion
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ammonia; Metabolic Disorder
Liver Failure, Chronic
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The present study will develop a method to assess ammonia metabolism by ammonia infusion and investigate ammonia production and clearance in healthy individuals and in patients with liver cirrhosis.


Eligibility criteria: Inclusion Criteria - Healthy controls:

* Alcohol \< 40g/day
* BMI \< 30
* Diseased or medicated

Inclusion Criteria - Patients with cirrhosis:

* Child-Pugh A or B cirrhosis
* BMI \< 30

Exclusion Criteria:

* Child-Pugh score C
* Kidney failure (eGFR \< 60 mL/min/1.73m2)
* Overt hepatic encephalopathy or more than one previous 1 episode of overt hepatic encephalopathy
* Acute bacterial infection
* Cancer
* Diabetes
* Ammonia-targeted treatment of hepatic encephalopathy other than lactulose (including Rifaximin and branched-chain amino acids)

Primary outcomes:
measure: Rate of clearance (L/min) and production (micromol/min) of ammonia
timeFrame: 2 years
Secondary outcomes:
measure: Change in clearance (L/min) and production (micromol/min) of ammonia when measured while on ammonia modulating agents
timeFrame: 2 years
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Hepatology & Gastroenterology
Study officials:
References:
Clinical trial NCT02282072: PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction
Official title: PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Opioid Addiction
Lead sponsor: Beijing Pins Medical Co., Ltd
Sponsor class: INDUSTRY
Collaborators: name: Beijing Tiantan Hospital
First posted: 2014-11-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to verify efficacy and safety of a bilateral deep brain stimulation (DBS) of the Nucleus accumbens (NAc) as a treatment option for severe opioid addiction.


Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years old.
2. In accordance with the diagnostic standards of DSM-IV \& ICD-10 for addicted and DSM-IV for abstinence.
3. Qualitative urine detection for opioids showing positive result.
4. Cleared for 8 to 36 hours after their last drug taking.
5. Fully understood and signed on informed consent.

Exclusion Criteria:

1. Person with consciousness disorder on opioid abstinence, seriously aggressive, heavily dehydrated and intending to commit suicide.
2. Patients with serious liver and kidney dysfunction, pulmonary decompensation, or complicated with serious damage in other systems.
3. Patients with serious infectious disease.
4. Patients with history of serious neurological or psychiatrical diseases.
5. Person with history of HIV infection or serious malnutrition.
6. Dependent upon and addicted to multiple drugs.
7. Attended some other drug trials within one month.

Primary outcomes:
measure: Schedule for the Assessment of Negative Symptoms (SANS)
timeFrame: 6 month
Secondary outcomes:
measure: Chronic Hunger Scale
timeFrame: 6 month
measure: Beck Depression Inventory
timeFrame: 6 month
measure: Buss & Perry Aggression Questionnaire
timeFrame: 6 month
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine
state: Shanghai
Study officials:
affiliation: Tsinghua University
name: Li Luming, PhD
role: STUDY_CHAIR
References: